Vall d'Hebron
Search

Home > Research Programs > Breast Cancer Program Group

More groups

Breast Cancer Group

Strategic Goals

  1. Optimization of the treatment of breast cancer with the incorporation of new drugs aimed a biological targets.
  2. Optimization of multidisciplinary treatment in patients with stage I-III breast cancer, incorporating studies with translational objectives.
  3. Participation in the development of new chemotherapy drugs.
  4. Incorporation of proteomics and genomics platforms and platforms of circulating tumor cells in breast cancer studies.

Current objectives

  • Implement sequencing of tumors in patients with breast cancer.
  • Study the efficacy of inhibitors of the PI3K/mTOR pathway and their relationship with the mutational state.
  • Continue investigating the factors involved in resistance to anti-HER2 treatments and strategies aimed at reversing them.
  • Study the efficacy of PARP inhibitors in breast cancer.
  • Implement therapeutic strategies and clinical trials differentiated by tumor subtype.

Team

Javier Cortés

Principal Investigator

Medical Oncologists

  • José Baselga
  • Meritxell Bellet
  • Serena Di Cosimo
  • Patricia Gómez
  • José Pérez
  • Cristina Saura

Oncologist Surgeon

  • Isabel Rubio

Fellows

  • María Alsina
  • Leticia de Mattos
  • María Vidal

Publications

  • Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010 Mar; 28(7): 1131-7
  • Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2010 Mar; 28(7): 1138-44
  • Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010 Jul; 28(20): 3239-47
  • Leyland-Jones B, Colomer R, Trudeau ME, Wardley A, Latreille J, Cameron D, Cubedo R, Al-Sakaff N, Feyereislova A, Catalani O, Fukushima Y, Brewster M, Cortes J. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J. Clin. Oncol. 2010 Feb; 28(6): 960-6
  • Cortes J, Baselga J. How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer. J. Clin. Oncol. 2009 Nov; 27(33): 5492-4

All publications